Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
QSAM Biosciences, Inc. | General Counsel & Executive VP | Common Stock | 0 | $0 | $3.00 | May 2, 2024 | Direct |
QSAM Biosciences, Inc. | General Counsel & Executive VP | Series B | 4.56K | Jun 23, 2023 | Direct | ||
QSAM Biosciences, Inc. | General Counsel & Executive VP | Options to buy common stock | 255 | Feb 6, 2024 | Direct | ||
QSAM Biosciences, Inc. | General Counsel & Executive VP | Series B Convertible Preferred Stock | 0 | Feb 6, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
QSAM | QSAM Biosciences, Inc. | May 2, 2024 | 1 | $0 | 4 | May 2, 2024 | General Counsel & Executive VP |
QSAM | QSAM Biosciences, Inc. | Feb 6, 2024 | 2 | $0 | 4/A | Feb 14, 2024 | EVP Corp Dev & General Counsel |
QSAM | QSAM Biosciences, Inc. | Feb 6, 2024 | 2 | $0 | 4 | Feb 13, 2024 | EVP Corp Dev & General Counsel |
QSAM | QSAM Biosciences, Inc. | Jun 23, 2023 | 1 | $0 | 4 | Jun 23, 2023 | EVP Corp Dev & General Counsel |
QSAM | QSAM Biosciences, Inc. | Dec 31, 2022 | 1 | $0 | 4 | Jan 4, 2023 | General Counsel |
QSAM | QSAM Biosciences, Inc. | Mar 3, 2022 | 1 | $0 | 4 | Mar 7, 2022 | General Counsel |
QSAM | QSAM Biosciences, Inc. | Dec 31, 2021 | 6 | $400K | 5 | Feb 14, 2022 | General Counsel and Director, Director |